Research Article| Volume 98, ISSUE 2, SUPPLEMENT 1, 29S-32S, February 27, 1995

Download started.


The role of bone loss

  • Bente Juel Riis
    Requests for reprints should be addressed to Bente Juel Riis, M.D., Center for Clinical and Basic Research, Ballerup Byvej 222, 2750 Ballerup, Denmark.
    Center for Clinical and Basic Research, Ballerup Denmark
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.


      Our longitudinal studies of early postmenopausalwomen have shown that there are two characteristic groups. Approximately 35% lose significant amounts of bone mineral (the “fast losers”), whereas approximately 65% lose only a minor amount of bone mineral (the “normal losers”). The rate of bone loss in postmenopausal women may be indirectly assessed by use of a number of biochemical markers. New markers have recently been developed, i.e., more specific and robust markers of both bone resorption and formation. The urinary concentration of degradation products of type I collagen and osteocalcin assays that are stable in serum may optimize the procedure to assess the rate of loss. We and others have shown that these markers correlate to the rate of bone loss with fairly high r values. A prospective 12-year study revealed that the fast bone losers still had significantly higher bone turnover than the normal bone losers. The role of baseline bone mass and rate of loss on fracture risk was evaluated. The data showed that a low baseline bone mass (below -1 SD) and a fast rate of loss predisposed to fracture to the same extent with an odds ratio of approximately 2. A combination of a low baseline bone mass and a fast rate of loss increased the odds ratio of having a fracture. In conclusion, these data suggest that a low bone mass and a fast rate of bone loss play equal roles for the future risk of fracture.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kanis J.A.
        • Melton L.J.
        • Christiansen C.
        • Johnston C.C.
        • Khaltaev N.
        The diagnosis of osteoporosis.
        J Bone Min Res. 1994; 9: 1137-1141
        • Melton L.J.
        • Chao E.Y.S.
        • Lane J.
        Biomechanical aspects of fractures.
        in: Riggs B.L. Melton L.J. Osteoporosis: Etiology, Diagnosis and Management. Raven Press, New York1988: 111-131
        • Nachtigall L.E.
        • Nachtigall R.H.
        • Nachtigall R.D.
        • Bechman E.M.
        Estrogen replacement therapy. I. A 10-year prospective study in the relationship to osteoporosis.
        Obstet Gynecol. 1979; 53: 277-281
        • Lindsay R.
        • Hart D.M.
        • Forrest C.
        • Baird C.
        Prevention of spinal osteoporosis in oophorectomized women.
        Lancet. 1980; ii: 1151-1154
        • Hui S.L.
        • Slemenda C.W.
        • Johnston Jr, C.C.
        Age and bone mass as predictors of fracture in a prospective study.
        J Clin Invest. 1988; 81: 1804-1809
        • Ross P.R.
        • Wasnich R.D.
        • Vogel J.M.
        Detection of prefracture spinal osteoporosis using bone mineral absorptiometry.
        J Bone Min Res. 1988; 3: 1-11
        • Raisz L.G.
        Assessment of the risk of osteoporosis at the menopause: therapeutic consequences.
        Osteoporosis International. 1994; : S53-S57
        • Christiansen C.
        • Riis B.J.
        • Rødbro P.
        Prediction of rapid bone loss in postmenopausal women.
        Lancet. 1987; i: 1105-1108
        • Christiansen C.
        • Riis B.J.
        • Rødbro P.
        Screening procedure for women at risk of developing postmenopausal osteoporosis.
        Osteoporosis International. 1990; 1: 35-40
        • Nilas L.
        • Christiansen C.
        Bone mass and its relationship to age and the menopause.
        J Clin Endocrinol Metab. 1987; 65: 697-702
        • Civitelli R.
        • Gonnelli S.
        • Zacchei F.
        • et al.
        Bone turnover in postmenopausal osteoporosis: effect of calcitonin treatment.
        J Clin Invest. 1988; 82: 1268-1274
        • Bonde M.
        • Qvist P.
        • Fledelius C.
        • Riis B.J.
        • Christiansen C.
        Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps™)-follow up on hormone replacement therapy andosteoporosis risk assessment.
        J Clin Endocrinol Metab. 1994; (in press)
        • Qvist P.
        • Bonde M.
        • Rosenqvist C.
        • Christiansen C.
        Use of a new biochemical marker (CrossLaps) for the estimation of rate of postmenopausal bone loss.
        J Bone Min Res. 1994; 1: S334
        • Kraenzlin M.E.
        • Kraenzlin C.A.
        • Haas H.G.
        Comparison of the utility of various biochemical markers to predict bone loss in clinical practice.
        J Bone Min Res. 1994; 1: S157
        • Hansen M.A.
        • Overgaard K.
        • Riis B.J.
        • Christiansen C.
        Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study.
        Br Med J. 1991; 303: 961-964